These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11471359)

  • 41. [Schizophrenic patients' length of stay: mental health care implication and medicoeconomic consequences].
    Capdevielle D; Boulenger JP; Villebrun D; Ritchie K
    Encephale; 2009 Sep; 35(4):394-9. PubMed ID: 19748377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Telemonitoring of cardiovascular diseases in Germany. Standing position and perspectives].
    Helms TM; Zugck C; Pelleter J; Ronneberger DL; Korb H
    Herz; 2007 Dec; 32(8):641-9. PubMed ID: 18060611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using Six Sigma to make a difference in health care quality.
    Simmons JC
    Qual Lett Healthc Lead; 2002 Apr; 14(4):2-10, 1. PubMed ID: 12001806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C; Stafford RS; Alexander GC
    Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Progress in therapy, innovations and economics of health].
    Giri I
    Therapie; 2001; 56(2):107-9. PubMed ID: 11471360
    [No Abstract]   [Full Text] [Related]  

  • 49. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urgent work needed to rebuild health care systems.
    Rassool GH
    J Adv Nurs; 2004 May; 46(4):456-8. PubMed ID: 15152646
    [No Abstract]   [Full Text] [Related]  

  • 51. [Sociological reflections: criticism of the health system].
    Ziegler J
    Krankenpfl Soins Infirm; 1983 Jan; (1):34-5. PubMed ID: 6300525
    [No Abstract]   [Full Text] [Related]  

  • 52. [The French National Medicines Assessment Committee, innovation and therapeutic progress].
    Bouvenot G
    Therapie; 2006; 61(1):13-6. PubMed ID: 16792149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Innovation and therapeutic progress].
    Revuz J
    Ann Dermatol Venereol; 2006 Feb; 133(2):111-2. PubMed ID: 16508592
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug therapy often cost-effective.
    Arkinstall WW
    CMAJ; 1996 Sep; 155(5):512. PubMed ID: 8804254
    [No Abstract]   [Full Text] [Related]  

  • 55. [Therapeutic progress, innovations and health economics. Introduction the the Third APNET Conference].
    Queneau P
    Therapie; 2001; 56(2):85-8. PubMed ID: 11471378
    [No Abstract]   [Full Text] [Related]  

  • 56. Faded promises: the challenge of deadopting low-value care.
    Roman BR; Asch DA
    Ann Intern Med; 2014 Jul; 161(2):149-50. PubMed ID: 24781317
    [No Abstract]   [Full Text] [Related]  

  • 57. [Pharmaceutical care].
    Vervaeren J
    J Pharm Belg; 1996; 51(4):208-15. PubMed ID: 8965251
    [No Abstract]   [Full Text] [Related]  

  • 58. Novelty seeking for novelty's sake.
    Wang W; Eldridge MAG; Richmond BJ
    Nat Neurosci; 2022 Jan; 25(1):7-8. PubMed ID: 34903881
    [No Abstract]   [Full Text] [Related]  

  • 59. [Innovation in the health area].
    Pons Ràfols JM
    Med Clin (Barc); 2010 Nov; 135(15):697-9. PubMed ID: 20036400
    [No Abstract]   [Full Text] [Related]  

  • 60. On criteria to evaluate the therapeutic innovation of drugs.
    Motola D; Montanaro N
    Br J Clin Pharmacol; 2021 May; 87(5):2403-2404. PubMed ID: 33219565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.